Abstract:Ovarian cancer is a gynecological malignant tumor with the highest mortality rate, and chemotherapy resistance seriously affects patient therapeutic outcomes. It has been shown that the high expression of anti‐apoptotic proteins Bcl‐2 and Bcl‐xL is closely related to ovarian cancer chemotherapy resistance. Therefore, reducing Bcl‐2 and Bcl‐xL expression levels may be essential for reversing drug resistance in ovarian cancer. ABT‐737 is a BH3‐only protein mimetic, which can effectively inhibit the expression of the anti‐apoptotic proteins Bcl‐xL and Bcl‐2. Although it has been shown that ABT‐737 can increase the sensitivity of ovarian cancer cells to cisplatin, the specific molecular mechanism remains unclear and requires further investigation. In the present study, the results revealed that ABT‐737 can significantly increase the activation levels of JNK and ASK1 induced by cisplatin in A2780/DDP cells, which are cisplatin‐resistant ovarian cancer cells. Inhibition of the JNK and ASK1 pathway could significantly reduce cisplatin cytotoxicity increased by ABT‐737 in A2780/DDP cells, while inhibiting the ASK1 pathway could reduce JNK activation. In addition, it was further determined that ABT‐737 could increase reactive oxygen species (ROS) levels in A2780/DDP cells induced by cisplatin. Furthermore, the inhibition of ROS could significantly reduce JNK and ASK1 activation and ABT‐737‐mediated increased cisplatin cytotoxicity in A2780/DDP cells. Overall, the current data identified that activation of the ROS‐ASK1‐JNK signaling axis plays an essential role in the ability of ABT‐737 to increase cisplatin sensitivity in A2780/DDP cells. Therefore, upregulation the ROS‐ASK1‐JNK signaling axis is a potentially novel molecular mechanism by which ABT‐737 can enhance cisplatin sensitivity of ovarian cancer cells. In addition, the present research can also provide new therapeutic strategies and new therapeutic targets for patients with cisplatin‐resistant ovarian cancer with high Bcl‐2/Bcl‐xL expression patterns.

Inhibition of AKT Sensitizes Chemoresistant Ovarian Cancer Cells to Cisplatin by Abrogating S and G2/M Arrest.

Checkpoint Kinase Inhibitor AZD7762 Enhance Cisplatin-Induced Apoptosis in Osteosarcoma Cells.

Akt-Mediated Cisplatin Resistance in Ovarian Cancer: Modulation of p53 Action on Caspase-Dependent Mitochondrial Death Pathway

The involvement of Bcl-2 family proteins in AKT-regulated cell survival in cisplatin resistant epithelial ovarian cancer

Chaetoglobosin K Induces Apoptosis and G2 Cell Cycle Arrest Through P53-Dependent Pathway in Cisplatin-Resistant Ovarian Cancer Cells.

Overexpression of AKT decreases the chemosensitivity of gastric cancer cells to cisplatin in vitro and in vivo.

Pharmacologic inhibition of Akt in combination with chemotherapeutic agents effectively induces apoptosis in ovarian and endometrial cancer cell lines

Knockdown of Cip2a Sensitizes Ovarian Cancer Cells to Cisplatin: an in Vitro Study

PGC1 Promotes Cisplatin Resistance in Ovarian Cancer by Regulating the HSP70/HK2/VDAC1 Signaling Pathway

PGC1α Promotes Cisplatin Resistance in Ovarian Cancer by Regulating the HSP70/HK2/VDAC1 Signaling Pathway

Akt Inhibitor MK-2206 Enhances the Effect of Cisplatin in Gastric Cancer Cells.

ABT‐737 increases cisplatin sensitivity through the ROS‐ASK1‐JNK MAPK signaling axis in human ovarian cancer cisplatin‐resistant A2780/DDP cells

ROS-regulated phosphorylation of ITPKB by CAMK2G drives cisplatin resistance in ovarian cancer

Pretreatment With The.- Secretase Inhibitor Dapt Sensitizes Drug- Resistant Ovarian Cancer Cells To Cisplatin By Downregulation Of Notch Signaling

Inhibition of PI3K/Akt/mTOR signaling pathway enhances the sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin in vitro.

Suppression of chloride channel 3 expression facilitates sensitivity of human glioma U251 cells to cisplatin through concomitant inhibition of Akt and autophagy.

Knockdown of Akt Sensitizes Osteosarcoma Cells to Apoptosis Induced by Cisplatin Treatment

Twist2 Contributes To Cisplatin-Resistance Of Ovarian Cancer Through The Akt/Gsk-3 Beta Signaling Pathway

Novel Platinum Nanoclusters Activate PI3K/AKT/mTOR Signaling Pathway-Mediated Autophagy for Cisplatin-Resistant Ovarian Cancer Therapy

RNAi Knockdown of the Akt1 Gene Increases the Chemosensitivity of Gastric Cancer Cells to Cisplatin Both in Vitro and in Vivo

Induction of Autophagy Contributes to Cisplatin Resistance in Human Ovarian Cancer Cells